Showing results (21-30 of 43) with videos related to
Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2011
Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trialSeza A Gulec, Steven J Cohen, Kenneth L Pennington, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II resultsFranck Morschhauser, John P Leonard, Luis Fayad, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot StudyElizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.Rheumatology (Oxford, England)|April 2, 2013
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-upDaniel J Wallace, Caroline Gordon, Vibeke Strand, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2006
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphomaSandra J Strauss, Frank Morschhauser, Juergen Rech, et al.Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie Ketas, et al.British Journal of Haematology|April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphomaBeth A Christian, Ming Poi, Jeffrey A Jones, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2015
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid TumorsAlexander N Starodub, Allyson J Ocean, Manish A Shah, et al.Pageof 5